Sermorelin nasal spray bioavailability is low—often a small fraction of injected dosing. Learn what limits absorption, what research shows, and safety steps.
Sermorelin nasal spray bioavailability is low — generally estimated at roughly 1% to 10% of the administered dose, compared with the much higher absorption seen after subcutaneous injection. That range comes from how similarly sized peptides behave in the nose rather than from large human studies of intranasal sermorelin, because those studies do not exist. Sermorelin's molecular size, its short half-life, and the nose's natural defenses all work against reliable absorption.
What "Bioavailability" Actually Measures
Bioavailability is the percentage of a dose that reaches the bloodstream in an active form. A 300 mcg spray, tablet, or injection does not mean 300 mcg of active peptide is circulating — the route of administration decides how much survives the trip.
For any nasal spray, three things have to go right:
- The peptide must cross the nasal epithelium instead of being swept away.
- It must survive enzymes in nasal mucus and tissue.
- It must reach systemic circulation intact.
Sermorelin clears all three hurdles poorly. That is why comparisons like sermorelin nasal spray vs injection usually come down to one question: how much peptide actually reaches the blood.
Why Sermorelin Absorbs Poorly Through the Nose
Molecular size
Sermorelin is a 29-amino-acid peptide with a molecular weight of about 3,358 daltons. Nasal absorption drops off sharply for molecules above roughly 1,000 daltons, so sermorelin sits well past the point where passive diffusion through the nasal lining works efficiently.
Enzymatic breakdown
The nasal cavity contains peptidases, including enzymes that clip GHRH analogs at specific points. A meaningful share of every intranasal dose is degraded before it ever reaches the bloodstream.
Mucociliary clearance
Tiny hair-like cilia move mucus toward the throat, clearing the nasal surface every 15 to 20 minutes. Peptide that lands on the mucus layer but does not cross quickly gets swallowed and digested.
Limited spray volume
A nasal spray delivers roughly 25 to 150 microliters per nostril. Larger volumes simply run down the back of the throat, so a bigger squirt does not translate into proportionally more absorption.
Nasal Spray vs Subcutaneous Injection
Subcutaneous injection is the delivery route used in nearly all clinical research on sermorelin, and it remains the reference standard for absorption.
| Factor | Sermorelin nasal spray (estimated) | Subcutaneous injection |
|---|---|---|
| Bioavailability | Roughly 1%–10%, formulation dependent | Substantially higher; the reference route |
| Dose needed for a comparable effect | Often many times higher on paper | Standard microgram dosing |
| Consistency between doses | High variability | More predictable |
| Onset | Variable and often blunted | Rapid, typically within 15–30 minutes |
| FDA-approved product | No | No current FDA-approved sermorelin product |
| Main advantage | Needle-free convenience | Reliable delivery |
Because so much of an intranasal dose is lost, nasal users often need far larger nominal amounts to produce any measurable change in IGF-1 or growth hormone. Whether that tradeoff is worth it is a personal and clinical decision, not a settled scientific one.
Formulation Factors That Change Nasal Absorption
Two sprays labeled with the same peptide can behave very differently. Permeation enhancers, pH, viscosity, and even spray technique can shift bioavailability by several-fold.
| Factor | Effect on absorption |
|---|---|
| Permeation enhancers (chitosan, cyclodextrins, alkylglycosides) | Can increase peptide uptake; human sermorelin data are largely absent |
| pH and osmolality | Affect peptide stability and how well it crosses the epithelium |
| Viscosity and gelling agents | Slower clearance can allow more time for absorption |
| Droplet size and spray plume | Determines how much lands on absorbent tissue versus the throat |
| Nasal congestion or allergies | Reduces absorption and increases variability |
| Spray technique and head position | Small differences change how much stays in the nose |
This is one reason peptide nasal sprays are hard to compare across products. People researching other peptides hit the same wall: discussions of semax nasal spray side effects or pt-141 nasal spray results often reflect formulation differences as much as the peptide itself.
What Low Bioavailability Means in Practice
When only a small fraction of each dose is absorbed, everything downstream gets harder.
- Cost per effective dose rises. A larger nominal dose is needed to deliver the same amount of peptide, and most of it is wasted.
- Results vary between people and between doses. Anatomy, congestion, and spray technique all change absorption.
- Bloodwork becomes the only real feedback. IGF-1 and growth hormone stimulation testing are how clinicians judge whether a meaningful amount is getting in.
- More is not automatically better. Raising the dose does not fix a delivery problem, and it increases the chance of side effects such as flushing, headache, or nasal irritation.
Safety, Regulation, and Sourcing
Sermorelin has no FDA-approved product on the U.S. market today; the original injectable brand was discontinued in 2008, and compounded sermorelin — including nasal sprays — is not FDA-approved for human use. No regulator has reviewed the nasal form for purity, potency, sterility, or dosing accuracy.
Research-peptide websites that sell nasal sprays are a particular concern. Labels are frequently inaccurate, sterility is not guaranteed, and these products are not intended for human use. DIY instructions such as how to make vip nasal spray circulate online, but home-mixed nasal formulations carry real risks of contamination, incorrect concentration, and nasal injury.
Anyone considering sermorelin should talk with a licensed healthcare professional about approved alternatives, appropriate monitoring, and the limits of what a nasal spray can realistically deliver.
Frequently Asked Questions
What is the bioavailability of sermorelin nasal spray?
Sermorelin nasal spray bioavailability is generally estimated at about 1% to 10% of the delivered dose. That range is an estimate based on how similarly sized peptides behave in the nose, not the result of large human pharmacokinetic studies of intranasal sermorelin. Subcutaneous injection delivers a substantially larger fraction of the dose.
Is sermorelin nasal spray as effective as injections?
No reliable head-to-head data show that nasal sermorelin matches injection. Because absorption is much lower, a nasal spray would need a considerably higher nominal dose to deliver the same amount of peptide, and results still tend to be more variable. Subcutaneous injection remains the route used in clinical research on sermorelin.
Is sermorelin nasal spray FDA approved?
No. Sermorelin has no FDA-approved product on the U.S. market, and compounded nasal sprays are not FDA-approved for human use. That means the nasal form has not been reviewed for purity, sterility, potency, or dosing accuracy.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.